novel oral anticoagulants, atrial fibrillation, deep vein thrombosis, pulmonary embolism, dabigatran, Pradaxa, rivaroxaban, Xarelto, apixaban, Eliquis, edoxaban, Savaysa, Lixiana
Novel oral anticoagulants (NOACs) are becoming popular management options for stroke prophylaxis in nonvalvular atrial fibrillation as well as deep vein thrombosis and pulmonary embolism treatment and prophylaxis. NOACs have similar efficacy to warfarin along with noninferior safety profiles. Patient comorbidities, size, renal and hepatic function, and concomitant drug regimen play a role in which NOAC a physician may choose.
Alsayegh LG. Novel oral anticoagulants for stroke prophylaxis and venous thromboembolism prevention and treatment. J Patient-Centered Res Rev. 2015;2:139-146. doi: 10.17294/2330-0698.1055
March 24th, 2015
June 2nd, 2015